Gabapentin

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Gabapentin
   1. Pharmacist Assessment Report
   2. Gabapentin: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Gabapentin: Known uses and market status in Australia

Summary

The TxGNN model’s candidates for Gabapentin (score ≥ 0.99) are all known uses that can be traced to a source. There is therefore currently no new predicted indication for this drug. The one known use found among the candidates is recorded as a relation in the knowledge graph.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
restless legs syndrome

Australia Market Information

Licence	Product	Dosage form	Status
1834M	Neurontin	Capsule 300 mg	Valid

Safety Considerations

• Drug Interactions: 100 interactions were identified, with the examples below drawn from the list provided.
  • Major: morphine (including liposomal morphine), most likely additive central nervous system and respiratory depression.
  • Moderate: dronabinol, nabilone, metoclopramide, opium and sibutramine.
  • Minor: cimetidine and antacids containing magnesium or aluminium (magnesium oxide, magnesium hydroxide, magnesium carbonate, aluminium hydroxide, magaldrate).
• Disease-related cautions (from the knowledge graph, not label text): anxiety disorder, neurotic disorder, dysthymic disorder, kidney disease and pyoureter. Gabapentin is renally cleared, so kidney function needs attention.

Please refer to the TGA-approved Product Information (PI) for key warnings and contraindications, which were not available in the data compiled for this report.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---